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Nine carbapenem-resistant Enterobacteriaceae isolates collected from eight patients in 27 
five German hospitals were investigated. Six isolates produced the OXA-48 28 
carbapenemase, and three isolates produced OXA-162 that is a point mutant of OXA-48. 29 
Both carbapenemase genes were located on IncL/M-type conjugative plasmids. Insertion 30 
sequence IS1999 (truncated or not by IS1R) was located upstream of the blaOXA-48/-162 31 
genes in all isolates. PFGE typing indicated a clonal transmission of an OXA-48 32 
producing Klebsiella pneumoniae strain in two hospitals. 33 
34 
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Carbapenem resistance in Enterobacteriaceae is based on various mechanisms that 35 
may involve up-regulation of efflux pumps or loss of porins. Most prevalent is the acquisition 36 
of carbapenem-hydrolyzing enzymes, or carbapenemases. Some commonly identified 37 
carbapenemases are KPC-, NDM- and OXA-48-type enzymes whose respective genes are 38 
located on plasmids that enable the transfer between different enterobacterial species (19). 39 
The OXA-48 carbapenemase was first described in Klebsiella pneumoniae epidemic isolates 40 
from Turkey and then in several European countries such as France and Belgium. Recently, it 41 
has been also identified from enterobacterial isolates recovered from non-European countries, 42 
such as Lebanon, Tunisia, Senegal, Morocco, Israel and India (2, 5, 9, 10, 12, 18). In addition 43 
to K. pneumoniae, OXA-48 has been identified in Escherichia coli, Enterobacter cloacae, 44 
Citrobacter freundii, and Providencia rettgeri (2). This enzyme is able to hydrolyze 45 
penicillins and carbapenems but possess poor activity against broad-spectrum cephalosporins. 46 
Multidrug-resistance in OXA-48 producing strains is often resulting from co-production of 47 
various resistance mechanisms, in particular extended-spectrum β-lactamases (ESBLs) and 48 
other resistance determinants. 49 
Here we report on the molecular analysis of carbapenem-resistant Enterobacteriaceae 50 
isolates that have been recovered in Germany between 2008 and 2010 and sent to the Robert 51 
Koch Institute, Wernigerode, for further characterization. Nine isolates, being E. coli (n=2), 52 
K. pneumoniae (n=4), Raoultella ornithinolytica (n=1), C. freundii (n=1) and E. cloacae 53 
(n=1) were selected since they gave negative phenotypical tests for production of metallo-β-54 
lactamases or KPC enzyme production (MBL-Etest, bioMérieux, Nürtingen, Germany; 55 
KPC+MBL Confirm ID Kit, Alere GmbH, Switzerland).  56 
In April and May 2008, two E. coli isolates were isolated from wound swab and secretion 57 
from tracheal cannula (colonization) in two hospitals in Berlin (hospitals A and B). One 58 
patient developed sepsis but recovered. The second patient exhibiting several co-morbidity 59 
factors developed sepsis and ventilator-associated pneumonia and was treated with various 60 
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antibiotics (tigecycline, piperacillin/sulbactam, meropenem). In addition, one R. 61 
ornithinolytica recovered from blood culture and one C. freundii recovered from broncho-62 
alveolar lavage were isolated from a 67-year-old patient in hospital A in September 2009.  63 
Between November 2009 and January 2010, four multidrug-resistant K. pneumoniae were 64 
sent in from intensive care units of two hospitals (hospitals C and D) located within distance 65 
of 40 km in the federal state of North Rhine-Westphalia. The strains had been isolated from 66 
urine cultures or tracheal aspirations of four different patients. These patients all presented 67 
with underlying diseases (myocardial infarction, congestive heart failure, plasmacytoma) and 68 
two patients had previously received meropenem. Additionally, an E. cloacae strain was 69 
isolated in 2009 from a drainage swab in hospital E which is located in South Germany. None 70 
of the patients reported any link with Turkey, one patient (E. coli, hospital B) came from 71 
Syria and another patient (E. cloacae, hospital E) from Libya. 72 
 Antimicrobial susceptibility testing of ten antibiotics (ampicillin, cefoxitin, 73 
cefotaxime, ceftazidime, gentamicin, kanamycin, chloramphenicol, tetracycline, 74 
ciprofloxacin, and sulfamethoxazole/trimethoprim) was determined by broth microdilution 75 
according to the CLSI guidelines (3). MIC determinations for carbapenems (imipenem, 76 
meropenem) were performed by Etest (bioMérieux). Occurrence of β-lactamases was detected 77 
by PCR amplification and sequencing of ESBL genes (blaTEM, blaSHV, blaCTX-M, blaOXA) and 78 
several carbapenemase genes like blaVIM, blaIMP, blaNDM-1, blaKPC, and blaOXA-48 (6, 13, 14). 79 
Identification of qnr-like genes encoding plasmid-mediated quinolone resistance determinants 80 
was performed as described (13). Transfer of resistance was performed by broth mating 81 
assays using a sodium azide-resistant E. coli J53 recipient (4). Plasmid DNA of clinical 82 
isolates and transconjugants was isolated using the Qiagen Plasmid Mini Kit (Qiagen, Hilden, 83 
Germany). Southern hybridization of the plasmids using DIG-labelled blaOXA-48-specific 84 
probes and signal detection using CDP-Star were performed following the manufacturer’s 85 
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guidelines (Roche Diagnostics Ltd, West Sussex, UK). In addition, all nine isolates were 86 
typed by pulsed-field gel electrophoresis (PFGE) using XbaI-restricted whole genomic DNA. 87 
Both E. coli isolates were resistant to carbapenems but remained susceptible to 88 
expanded-spectrum cephalosporins. All other isolates were resistant to cefotaxime and 89 
ceftazidime and either resistant (K. pneumoniae isolates) or of intermediate susceptibility to 90 
imipenem and meropenem. Co-resistances to fluoroquinolones (seven isolates), 91 
aminoglycosides (nine isolates) and sulfamethoxazole/trimethoprim (three isolates) were 92 
frequently observed (Table 1). 93 
PCR and sequencing analysis revealed that the three isolates from hospital A (E. coli, 94 
C. freundii, R. ornithinolytica) harbored the blaOXA-162 gene whereas the blaOXA-48 gene was 95 
detected in E. cloacae isolates and the four K. pneumoniae isolates (Table 1). OXA-162 is a 96 
recently identified OXA-48-type variant, differing from OXA-48 by a Thr to Ala substitution 97 
at position 224 (DBL numbering; 17). Additionally, the blaTEM-1 gene was identified in eight 98 
out of the nine isolates, and the blaSHV-11 and blaOXA-9 genes were identified in all the K. 99 
pneumoniae isolates. Furthermore, genes encoding ESBLs SHV-5 or CTX-M-15 were found 100 
in isolates being resistant to ceftazidime and cefotaxime (Table 1). The qnrB1 gene was 101 
additionally identified from the E. cloacae isolate.  102 
Conjugation assays were successful for all isolates and allowed to identify blaOXA-162- 103 
and blaOXA-48-carrying plasmids which size being of ca. 60 kb in all isolates transferred into E. 104 
coli recipients (Figure 1). No other resistance genes were co-transferred on these plasmids. 105 
PCR-based typing targeting genes identified from other blaOXA-48-bearing plasmids as recently 106 
described (15) showed that the genes blaOXA-48 and blaOXA-162 identified in the present study 107 
corresponded to IncL/M-type plasmids, further reinforcing the hypothesis that the current 108 
spread of the blaOXA-48-like genes in different strain backgrounds and different countries is 109 
mainly the consequence of the diffusion of an epidemic plasmid. Analysis of the upstream-110 
located genetic environment of the blaOXA-48 and blaOXA-162 genes (1, 2) revealed the presence 111 
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of insertion sequence IS1999 in the four K. pneumoniae isolates, although IS1999 was 112 
truncated by insertion sequence IS1R in all other isolates as described previously (2). 113 
The antibiotic resistance pattern and β-lactamase content of the four K. pneumoniae 114 
isolates recovered from two different hospitals were identical. Additional sequencing of outer 115 
membrane protein genes ompK35 and ompK36 performed as described (11) revealed the 116 
disruption of ompK36 by an IS-insertion in all four K. pneumoniae, therefore resulting in 117 
porin loss and increased MIC values for carbapenems, as previously described (11). The 118 
higher MIC values for carbapenems observed for the E. coli and E. cloacae clinical isolates 119 
compared to their respective transconjugants may likely be attributed to permeability defects 120 
for the clinical isolates, related to porin loss or efflux mechanisms. By PFGE typing, identical 121 
restriction patterns were observed for all four isolates, indicating a clonal spread of a 122 
multidrug-resistant K. pneumoniae strain. No link between the four patients from the two 123 
hospitals located at 40 km distance could be evidenced. 124 
 The present study showed the emergence of OXA-48 and OXA-162 producers 125 
among enterobacterial isolates in Germany. Although spread of OXA-48-producers has been 126 
recently identified in different countries from the Mediterranean area and Western Europe (2, 127 
8), it is noteworthy that Turkey represents a main reservoir. Considering the high frequency of 128 
population exchanges between Germany and Turkey, we speculate that at least some of the 129 
isolates currently emerging in Germany could originate from Turkey. We identified the novel 130 
OXA-162 enzyme which is a point mutant derivative of OXA-48, and that has been identified 131 
also recently in Turkey according to the GenBank databases (Accession numbers HM015773 132 
and GU197550). Identification of a same blaOXA-162-carrying plasmid in R. ornithinolytica and 133 
C. freundii isolated from one patient may have resulted from horizontal gene transfer. We 134 
further detected loss of porin OmpK36 in K. pneumoniae as a combined mechanism of 135 
carbapenem resistance, as identified in K. pneumoniae 11978 (7, 16). 136 
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Here, we identified carbapenemases OXA-48 and OXA-162 in different multidrug-137 
resistant Enterobacteriaceae species that co-produce ESBL and other plasmid-mediated 138 
resistance determinants like Qnr. We observed dissemination of blaOXA-48-like genes by 139 
conjugative plasmid transfer as well as the regional spread and of a multidrug-resistant OXA-140 
48 producing K. pneumoniae clone. Because of limited therapeutic options and higher 141 
mortality caused by these carbapenem resistant Enterobacteriaceae continuous surveillance 142 
and molecular characterisation of OXA-48 producers are needed to shed up light upon all 143 
transmission ways in Germany and over continents. Taking in account the relationships 144 
between Germany and many countries located in North Africa and the Middle-East, this study 145 
underlines the need to detect OXA-48 producers as early as possible. 146 
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Figure 1: Plasmid preparations from OXA-carbapenemase producing clinical strains 217 
and transconjugants (Tc). A), native plasmid preparation of clinical strains and 218 
transconjugants in agarose gel; B), Southern hybridisation of plasmids of clinical strains and 219 
transconjugants on nylon membrane with a DIG-labelled blaOXA-48-probe; C), native plasmid 220 
preparation of clinical strains isolated in 2010 and transconjugants in agarose gel; M,  plasmid 221 
marker E. coli K12J53 V517 (53.000 bp plasmid); N, plasmid marker E. coli K12J53 V517 + 222 
E. coli K12J53 R222 (53.000 bp and 90.000 bp plasmid); S, DIG-labelled Molecular Weight 223 
Marker II (Roche Diagnostics Ltd, West Sussex, UK); 1, E. coli 131/08; 2, Tc 131/08; 3, E. 224 
coli 84/08; 4, Tc 84/08; 5, R. ornithinolytica 215/09; 6, Tc 215/09; 7, C. freundii 216/09; 8, 225 
Tc 216/09; 9, K. pneumoniae 229/09; 10, E. cloacae 1/10; 11, Tc 1/10; 12, K. pneumoniae 226 
16/10; 13, Tc 16/10. Positive hybridisation signals are framed. Hybridisation signals less than 50 227 






Table 1. Phenotypical and genotypical characteristics of OXA-carbapenemase producing clinical isolates and transconjugants 233 
 234 
No. Species Hospital Year β-lactamases Antimicrobial resistances MICIPM [mg/L]
4 MICMPM [mg/L]
4 PFGE type 
84/08   E. coli A 2008 OXA-162  TEM-1  AMP FOX GEN CMP OTE CIP SXT 8 16 1 
215/091   R. ornithinolytica A 2009 OXA-162  TEM-1 OXA-1 SHV-5 AMP CTX CAZ KAN CMP CIP 4 4 2 
216/091   C. freundii A 2009 OXA-162  SHV-5 AMP FOX CTX CAZ GEN CMP  2 2 3 
131/08  E. coli B 2008 OXA-48  TEM-1  OXA-1 AMP GEN CMP OTE SXT 32 32 4 
229/09   K. pneumoniae C 2009 OXA-48  TEM-1  OXA-9  SHV-11  CTX-M-15 AMP FOX CTX CAZ GEN KAN AMK CIP >32 >32 5 
238/09 K. pneumoniae C 2009 OXA-48  TEM-1  OXA-9  SHV-11  CTX-M-15 AMP FOX CTX CAZ GEN KAN AMK CIP >32 >32 5 
239/09 K. pneumoniae C 2009 OXA-48  TEM-1  OXA-9  SHV-11  CTX-M-15 AMP FOX CTX CAZ GEN KAN AMK CIP >32 >32 5 
16/10  K. pneumoniae D 2010 OXA-48  TEM-1  OXA-9  SHV-11  CTX-M-15 AMP FOX CTX CAZ GEN KAN AMK CIP 32 >32 5 
1/10  E. cloacae E 2010 OXA-48  TEM-1  CTX-M-15 AMP FOX CTX CAZ GEN KAN CMP CIP SXT 4 8 6 
Tc 84/08  E. c. J53 - - OXA-162  TEM-1 AMP GEN OTE SXT 0.25 1 - 
Tc 131/08  E. c. J53 - - OXA-48    TEM-1 AMP GEN CMP 0.25 0.5 - 
Tc2 E. c. J53 - - OXA-48 or OXA-162 AMP 1 1 - 
Rc3 E. c. J53 - - - - ≤0.063 ≤0.063 - 
 235 
MIC, minimum inhibitory concentration; Tc, transconjugant; 1, isolates from the same patient; 2, characteristics of transconjugants Tc 215/09, Tc 216/09, Tc 229/09, Tc 238/09, Tc 239/09, Tc 16/10, Tc 1/10; 3, recipient E. 236 
coli J53 resistant to sodium azide; 4, determined by Etest; AMP, ampicillin; FOX, cefoxitin; CTX, cefotaxime; CAZ, ceftazidime; GEN, gentamicin; KAN, kanamycin; AMK, amikacin; CMP, chloramphenicol; OTE, 237 
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Figure 1: Plasmid preparations from OXA-carbapenemase producing clinical
strains and transconjugants (Tc). A), native plasmid preparation of strains 1-9 in
agarose gel; B), Southern hybridisation of plasmids (strains 1-9) on nylon membrane
with a DIG-labelled blaOXA-48-probe; C), native plasmid preparation of strains 10-13
in agarose gel; M, plasmid marker E. coli K12J53 V512; N, plasmid marker E. coli
K12J53 V512 + E. coli K12J53 R222; S, DIG-labelled Molecular Weight Marker II
(Roche Diagnostics Ltd, West Sussex, UK); 1, E. coli 131/08; 2, Tc 131/08; 3, E. coli
84/08; 4, Tc 84/08; 5, K. oxytoca 215/09; 6, Tc 215/09; 7, C. freundii 216/09; 8, Tc
216/09; 9, K. pneumoniae 229/09; 10, E. cloacae 1/10; 11, Tc 1/10; 12, K. pneumoniae
16/10; 13, Tc 16/10. Positive hybridisation signals are framed.
